title: Treatment of acute kidney injury with cast nephropathy.
abstract: Nearly 50% of patients with multiple myeloma develop renal disease; acute kidney injury (AKI) from cast nephropathy, or "myeloma kidney" is the most common type. Development of AKI is associated with worse 1-year survival and reduces the therapeutic options available to patients. Therefore, there is a great need to develop more effective therapies. Cast nephropathy is due to the interaction and aggregation of filtered free light chains (FLCs) and Tamm- Horsfall protein (THP) causing intratubular obstruction and damage. The key to treating cast nephropathy is rapid lowering of FLCs as this correlates with renal recovery. Newer chemotherapy agents lower FLCs and have been referred to as "renoprotective". However there remains great interest in using various extracorporeal therapies to remove serum FLCs. Initially, therapeutic plasma exchange (TPE) was thought to improve renal outcomes in cast nephropathy based on small trials. The largest randomized trial of TPE, however, failed to show any benefit. A newer technique is extended high cut-off hemodialysis (HCO-HD). This modality uses a high molecular weight cut-off filter to remove FLCs. To date, trials with HCO-HD in patients with cast nephropathy have been encouraging. However, there are no randomized trials demonstrating the benefit of HCOHD when used in addition to newer chemotherapeutic regimens. Until these studies are available, HCO-HD cannot be recommended as standard of care.
authors.forename: Carl
authors.initials: C
authors.lastname: Walther
authors.forename: Amber S
authors.initials: AS
authors.lastname: Podoll
authors.forename: Kevin W
authors.initials: KW
authors.lastname: Finkel
mesh_terms: D058186:Acute Kidney Injury / Q000097:blood / Q000175:diagnosis / Q000209:etiology / Q000276:immunology / Q000628:therapy*; D006801:Humans; D007147:Immunoglobulin Light Chains / Q000378:metabolism; D007668:Kidney / Q000187:drug effects* / Q000276:immunology / Q000473:pathology; D009101:Multiple Myeloma / Q000097:blood / Q000150:complications* / Q000276:immunology; D010951:Plasma Exchange / Q000379:methods*; D020011:Protective Agents / Q000627:therapeutic use*; D006435:Renal Dialysis / Q000379:methods*; D016896:Treatment Outcome; D058949:Uromodulin / Q000378:metabolism
chemical_list: D007147:Immunoglobulin Light Chains; D020011:Protective Agents; C548612:UMOD protein, human; D058949:Uromodulin